|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Srini Anandakumar explores an approach for how sponsor’s operational data, coupled with syndicated data and Real World Evidence data, can enable predictive analytics on clinical cost drivers using a clinical big data and Machine Learning-enabled platform.
|
|
|
Jeff Zonderman explains how the characterization of mAbs at high concentration in clinically representative formulations, without the need for dilution or concern for interference from a formulation buffer’s excipient, is vital.
|
|
|
Paulo Lino, PhD, and João Henriques discuss the main development goals and present a framework for a streamlined development of amorphous solid dispersion formulations by spray drying.
|
|
|
Andrew Leber, PhD, Raquel Hontecillas, PhD, and Josep Bassaganya-Riera, PhD, say current IBD therapeutics have mediocre efficacy, poor maintenance of response, and damaging side effects, including cancer, infection, and death, resulting in an unmet clinical need for safer and more effective oral therapeutics.
|
|
|
|
|
|
|
|
|

JRS Pharma is a leading manufacturer of excipients, offering a complete portfolio of excipient solutions for the pharmaceutical and nutraceutical industries. Our excipients portfolio includes: high functionality excipients, binders, disintegrants, lubricants, functional fillers, thickeners, stabilizers, carriers, and coatings. In addition to our wide range of excipients, we offer excellent technical and formulation support to address the needs of our customers. Our innovative excipients and coatings, along with our formulation expertise, provide our customers with a complete portfolio of solutions for the development and manufacture of solid and liquid dosage forms. Click here for more.
|
|
|
|
|
|
 |
|
ABITEC Corporation, a global manufacturer of functional lipid excipients continues to pursue new technologies that solve various formulation challenges in the pharmaceutical market.
|
|
 |
|
Sol-Gel Technologies, Ltd. recently announced it has entered into a seventh collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc for the development, manufacturing, and commercialization of two new generic formulations of antibiotic foams.
|
|
 |
|
Biomunex Pharmaceuticals recently announced that it has established its US subsidiary, Biomunex Pharmaceuticals Inc., in Cambridge, MA.
|
|
 |
|
The Japanese medical device market is set to reach from $54.5 billion in 2018 to $74.7 billion in 2025, growing at a compound annual growth rate (CAGR) of 4.6% says GlobalData, a leading data and analytics company.
|
|
 |
|
Tim McLean, Senior Editor, Life Sciences BCC Research, say his company’s new type of market research report is far shorter — but hopefully it delivers the bigger picture.
|
|
|
|
|
Upcoming eNewsletter Features:
June 12 – Injection Devices
June 19 – Parenteral Contract Manufacturing
|
|
|
|
|
|
|
|